An increased neutrophil-lymphocyte ratio in Alzheimer's disease is a function of age and is weakly correlated with neocortical amyloid accumulation

Journal of Neuroimmunology

Volumn 273, Issue 1-2, 2014, Pages 65-71

  Rembach, Alan ^a   Watt, Andrew D ^a   Wilson, William J ^b   Rainey Smith, Stephanie ^f   Ellis, Kathryn A ^a,e   Rowe, Christopher C ^d   Villemagne, Victor L ^d   Macaulay, S Lance ^c   Bush, Ashley I ^a   Martins, Ralph N ^f   Ames, David ^e   Masters, Colin L ^a   Doecke, James D ^b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^c CSIRO   (Australia)

^d AUSTIN HEALTH   (Australia)

^e NATIONAL AGEING RESEARCH INSTITUTE   (Australia)

^f Sir James McCusker Alzheimer's Research Unit   (Australia)

Author keywords

Alzheimer's disease; Diagnosis; Haematology; Neocortical amyloid burden; Neuroinflammation

Indexed keywords

AGE; AGED; ALLELE; ALZHEIMER DISEASE; APOEEPSILON4 GENE; ARTICLE; COGNITION; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION COEFFICIENT; CORTICAL AMYGDALA; CROSS-SECTIONAL STUDY; DISEASE CLASSIFICATION; DISEASE DURATION; DISEASE MARKER; FEMALE; GENE; HEALTH STATUS; HUMAN; HUMAN CELL; INFLAMMATION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEMORY; MINI MENTAL STATE EXAMINATION; NEUTROPHIL LYMPHOCYTE RATIO; NON MEMORY COGNITIVE SCORE; PATHOPHYSIOLOGY; PHASE TRANSITION; POPULATION RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; RATING SCALE; SCORING SYSTEM; SEX DIFFERENCE;

ALZHEIMER'S DISEASE; DIAGNOSIS; HAEMATOLOGY; NEOCORTICAL AMYLOID BURDEN; NEUROINFLAMMATION;

AGED; AGED, 80 AND OVER; AGING; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANILINE COMPOUNDS; APOLIPOPROTEIN E4; CHI-SQUARE DISTRIBUTION; COGNITION DISORDERS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; LONGITUDINAL STUDIES; LYMPHOCYTES; MALE; MEMORY, EPISODIC; NEOCORTEX; NEUTROPHILS; PSYCHIATRIC STATUS RATING SCALES; THIAZOLES;

EID: 84904119177     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2014.05.005     Document Type: Article

References (54)

1. Akiyama H., et al. Inflammation and Alzheimer's disease. Neurobiol. Aging 2000, 21(3):383-421.
2. Alzheimer's Disease International World Alzheimer Report 2009, ADI, London. M. Prince, J. Jackson (Eds.).
3. Alzheimer's Disease International World Alzheimer Report 2010: The Global Impact of Dementia 2010, ADI, London. A. Wimo, M. Prince (Eds.).
4. Arima Y., et al. Regulation of immune cell infiltration into the CNS by regional neural inputs explained by the gate theory. Mediat. Inflamm. 2013, 2013:898165.
5. Bhat T., et al. Neutrophil to lymphocyte ratio and cardiovascular diseases: a review. Expert. Rev. Cardiovasc. Ther. 2013, 11(1):55-59.
6. Blennow K., de Leon M.J., Zetterberg H. Alzheimer's disease. Lancet 2006, 368(9533):387-403.
7. Cappellano G., et al. Immunity and inflammation in neurodegenerative diseases. Am. J. Neurodegener. Dis. 2013, 2(2):89-107.
8. Davydova T.V., et al. Phagocytic activity and state of bactericidal systems in polymorphonuclear leukocytes from patients with Alzheimer's disease. Bull. Exp. Biol. Med. 2003, 136(4):355-357.
9. Doecke J.D., et al. Blood-based protein biomarkers for diagnosis of Alzheimer disease. Arch. Neurol. 2012, 69(10):1318-1325.
10. Doody R.S., et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N. Engl. J. Med. 2014, 370(4):311-321.
11. Ellis K.A., et al. The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease. Int. Psychogeriatr. 2009, 21(4):672-687.
12. Enciu A.M., Popescu B.O. Is there a causal link between inflammation and dementia?. Biomed. Res. Int. 2013, 2013:316495.
13. Ferretti M.T., Cuello A.C. Does a pro-inflammatory process precede Alzheimer's disease and mild cognitive impairment?. Curr. Alzheimer Res. 2011, 8(2):164-174.
14. Fiala M., et al. Ineffective phagocytosis of amyloid-beta by macrophages of Alzheimer's disease patients. J. Alzheimers Dis. 2005, 7(3):221-232. (discussion 255-62).
15. Fodero-Tavoletti M.T., et al. Amyloid-β: the seeds of darkness. Int. J. Biochem. Cell Biol. 2011, 43(9):1247-1251.
16. Fulop T., Kekessy D., Foris G. Altered post-receptorial signal transduction mechanism under various stimulation in polymorphonuclear granulocytes of Alzheimer's disease. Mech. Ageing Dev. 1990, 52(2-3):277-285.
17. Guillot-Sestier M.V., Town T. Innate immunity in Alzheimer's disease: a complex affair. CNS Neurol. Disord. Drug Targets 2013, 12(5):593-607.
18. Hansson O., et al. Evaluation of plasma Abeta as predictor of Alzheimer's disease in older individuals without dementia: a population-based study. J. Alzheimers Dis. 2012, 28(1):231-238.
19. Hurd M.D., et al. Monetary costs of dementia in the United States. N. Engl. J. Med. 2013, 368(14):1326-1334.
20. Imtiaz F., et al. Neutrophil lymphocyte ratio as a measure of systemic inflammation in prevalent chronic diseases in Asian population. Int. Arch. Med. 2012, 5(1):2.
21. Jaremo P., et al. Alzheimer's disease is characterized by more low-density erythrocytes with increased volume and enhanced beta-amyloid x-40 content. J. Intern. Med. 2011, 270(5):489-492.
22. Kitazawa M., Yamasaki T.R., LaFerla F.M. Microglia as a potential bridge between the amyloid beta-peptide and tau. Ann. N. Y. Acad. Sci. 2004, 1035:85-103.
23. Kuyumcu M.E., et al. The evaluation of neutrophil-lymphocyte ratio in Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 2012, 34(2):69-74.
24. Lee K.S., et al. Peripheral cytokines and chemokines in Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 2009, 28(4):281-287.
25. Leuner K., et al. Peripheral mitochondrial dysfunction in Alzheimer's disease: focus on lymphocytes. Mol. Neurobiol. 2012, 46(1):194-204.
26. Lynch M.A. The impact of neuroimmune changes on development of amyloid pathology; relevance to Alzheimer's disease. Immunology 2014, 141(3):292-301. 10.1111/imm.12156.
27. McColl B.W., Rothwell N.J., Allan S.M. Systemic inflammatory stimulus potentiates the acute phase and CXC chemokine responses to experimental stroke and exacerbates brain damage via interleukin-1- and neutrophil-dependent mechanisms. J. Neurosci. 2007, 27(16):4403-4412.
28. McKhann G., et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34(7):939-944.
29. Nordstedt C., et al. Human neutrophil phagocytic granules contain a truncated soluble form of the Alzheimer beta/A4 amyloid precursor protein (APP). J. Biol. Chem. 1994, 269(13):9805-9810.
30. Petersen R.C., et al. Mild cognitive impairment: clinical characterization and outcome. Arch. Neurol. 1999, 56(3):303-308.
31. Prince M., et al. The global prevalence of dementia: a systematic review and metaanalysis. Alzheimers Dement. 2013, 9(1):63-75. (e2).
32. Rembach A., et al. Plasma amyloid-beta levels are significantly associated with a transition toward Alzheimer's disease as measured by cognitive decline and change in neocortical amyloid burden. J. Alzheimers Dis. 2014, 40(1):95-104. 10.3233/JAD-131802.
33. Rembach A., et al. Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimer's disease. Alzheimers Dement. 2014, 10(1):53-61.
34. Rubio-Perez J.M., Morillas-Ruiz J.M. A review: inflammatory process in Alzheimer's disease, role of cytokines. ScientificWorldJournal 2012, 2012:756357.
35. Salloway S., et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N. Engl. J. Med. 2014, 370(4):322-333.
36. Sarraf K.M., et al. Neutrophil/lymphocyte ratio and its association with survival after complete resection in non-small cell lung cancer. J. Thorac. Cardiovasc. Surg. 2009, 137(2):425-428.
37. Scali C., et al. Neutrophils CD11b and fibroblasts PGE(2) are elevated in Alzheimer's disease. Neurobiol. Aging 2002, 23(4):523-530.
38. Schwab C., McGeer P.L. Inflammatory aspects of Alzheimer disease and other neurodegenerative disorders. J. Alzheimers Dis. 2008, 13(4):359-369.
39. Selkoe D.J. Resolving controversies on the path to Alzheimer's therapeutics. Nat. Med. 2011, 17(9):1060-1065.
40. Solito E., Sastre M. Microglia function in Alzheimer's disease. Front. Pharmacol. 2012, 3:14.
41. Song C., et al. Alterations in immune functions during normal aging and Alzheimer's disease. Psychiatry Res. 1999, 85(1):71-80.
42. Sperling R.A., Jack C.R., Aisen P.S. Testing the right target and right drug at the right stage. Sci. Transl. Med. 2011, 3(111):111-133.
43. Sperling R.A., et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011, 7(3):280-292.
44. Strang F., et al. Amyloid plaques dissociate pentameric to monomeric C-reactive protein: a novel pathomechanism driving cortical inflammation in Alzheimer's disease?. Brain Pathol. 2012, 22(3):337-346.
45. Sultana R., et al. Lymphocyte mitochondria: towards identification of peripheral biomarkers in progression of Alzheimer disease, Free Radic. Biol. Med. 2013, 65:595-606. (Epub 2013 Aug 8). 10.1016/j.freeradbiomed.2013.08.001.
46. Swardfager W., et al. A meta-analysis of cytokines in Alzheimer's disease. Biol. Psychiatry 2010, 68(10):930-941.
47. Toledo J.B., et al. Factors affecting Abeta plasma levels and their utility as biomarkers in ADNI. Acta Neuropathol. 2011, 122(4):401-413.
48. Villain N., et al. Regional dynamics of amyloid-beta deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study. Brain 2012, 135(Pt 7):2126-2139.
49. Villemagne V.L., et al. Blood borne Aβ dimer correlates with clinical stage of Alzheimer's disease 2009.
50. Villemagne V.L., et al. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol. 2013, 12(4):357-367.
51. Vitte J., et al. Oxidative stress level in circulating neutrophils is linked to neurodegenerative diseases. J. Clin. Immunol. 2004, 24(6):683-692.
52. Walsh S.R., et al. Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. J. Surg. Oncol. 2005, 91(3):181-184.
53. Wilson E.H., Weninger W., Hunter C.A. Trafficking of immune cells in the central nervous system. J. Clin. Invest. 2010, 120(5):1368-1379.
54. Winblad B., et al. Mild cognitive impairment-beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J. Intern. Med. 2004, 256(3):240-246.